Pliant Therapeutics, Inc. (PLRX)

Pliant Therapeutics' stock price has significantly declined, with an 89.18% decrease between February 3, 2025, and January 30, 2026. Key events include promising interim results for PLN-101095, the departure of the Chief Medical Officer, the appointment of Minnie Kuo as COO, Q3 2025 earnings exceeding expectations, an update on BEACON-IPF, insider selling, and an average analyst rating of 'Reduce'.

Information regarding demand seasonality specifically for Pliant Therapeutics, Inc.'s products and services is limited, as revenue is tied to drug development progress. However, a seasonal timeframe has shown positive results compared to the benchmark in 4 out of 5 periods, outperforming the relative buy-and-hold performance of the stock by an average of 67.17% per year. This seasonal timeframe aligns with the broader Healthcare sector's period of seasonal strength, which typically runs from April 25 to December 4.

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for fibrotic diseases, utilizing a precision medicine strategy to target integrin-mediated signaling pathways. Their lead product candidate, PLN-74809 (bexotegrast), is in clinical trials for IPF and PSC, and their pipeline includes PLN-1474 for NASH-related liver fibrosis, PLN-101095 for solid tumors, and PLN-101325 for muscular dystrophies.

Pliant Therapeutics, Inc. is headquartered in Redwood City, California, and conducts clinical programs primarily in North America, with plans to expand patient enrollment globally.

Pliant Therapeutics' brand reputation has been affected by financial difficulties, bearish technical trends, and a 'Reduce' analyst consensus with an average target price of $3.25. MarketBeat's news sentiment score for Pliant Therapeutics is 1.94, which is higher than the average news sentiment score of 0.84 for Medical companies.

Pliant Therapeutics, Inc. has significant institutional ownership, with 97.30% of its stock held by institutions, including Tang Capital Management Llc, Woodline Partners LP, and Point72 Asset Management, L.P. Individual ownership by insiders accounts for 8.00% of the stock.